Business News, In Brief
Companies discuss their plans to move pipelines forward as the third quarter wraps up and they prepare for new launches and new indications in the coming year.
You may also be interested in...
As many observers expected, top-line results from a Phase III study show bapineuzumab doesn’t work in carriers of the ApoE4 gene, who are at highest risk for Alzheimer’s disease. An interim analysis of another Phase III study in carriers will now be “expedited,” and other studies of non-carriers will keep going, Pfizer says.
Regeneron’s five-year-old antibody partnership with Sanofi may be expensive, but it is starting to produce some interesting compounds in mid-to-late-stage clinical trials, with positive data to show.
Regeneron has designed the launch strategy of its bimonthly wet AMD injection Eylea to head off any reimbursement issues.